Development and validation of rapid molecular diagnostic test for nCoV19

Objectif

Rapid development of a molecular diagnostic test for Corona virus nCoV19 for near patient testing

Champ scientifique

• sciences médicales et de la santé › sciences de la santé › maladies infectieuses › virus à ARN › coronavirus

Programme(s)

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
• H2020-EU.3.1.3. - Treating and managing disease

Thème(s)

• SC1-PHE-CORONAVIRUS-2020 - Advancing knowledge for the clinical and public health response to the 2019-nCoV epidemic

Appel à propositions

H2020-SC1-PHE-CORONAVIRUS-2020
Voir d’autres projets de cet appel

Régime de financement

RIA - Research and Innovation action

Coordinateur

HIBERGENE DIAGNOSTICS LIMITED

Adresse

21 Palmerstown Gardens, Rathmines
DUBLIN 6 Dublin
Irlande

Type d’activité

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Contribution de l’UE

€ 643 796,25

Participants (3)

THE QUEEN'S UNIVERSITY OF BELFAST

United Kingdom

Contribution de l’UE

€ 36 012,50

Adresse

University Road Lanyon Building
BT7 1NN Belfast

Type d’activité

Higher or Secondary Education Establishments

IRCCS OSPEDALE POLICLINICO SAN MARTINO

Italie

Contribution de l’UE

€ 61 875

Adresse

Largo Rosanna Benzi 10
16132 Genova

Type d’activité

Research Organisations

SHENZHEN MEDCAPTAIN MEDICAL TECHNOLOGY

Chine

Contribution de l’UE

€ 189 921

Adresse

5158 West Shahe Road 12Th Floor Baiwang Research Bulling 1 Xili Nanshan
518055 Shenzhen

Type d’activité

Private for-profit entities (excluding Higher or Secondary Education Establishments)